Alx Oncology Holdings (ALXO) Return on Capital Employed (2020 - 2026)
Alx Oncology Holdings (ALXO) reported Return on Capital Employed of 92.55% for Q1 2026, up 2556.0% on a YoY basis from 3.48% in Q1 2025, and up 58.78% sequentially from 224.51% in Q4 2025.
Alx Oncology Holdings (ALXO) Return on Capital Employed (2020 - 2026) Analysis & Trends
Alx Oncology Holdings (ALXO) has 7 years of Return on Capital Employed data on file, last reported at 92.55% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 2556.0% year-over-year to 92.55%; the trailing twelve-month figure through Mar 2026 stood at 92.55% (up 2556.0% YoY), and the FY2025 full-year result was 131.91%, down 5127.0% from the prior year.
- Return on Capital Employed improved to 92.55% in Q1 2026, from 224.51% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 26.38% in Q1 2022 to a low of 224.51% in Q4 2025.
- A 5-year average of 91.46% and a median of 90.0% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed slumped 12841 bps in 2025 and soared 2556 bps in 2026, its largest moves.
- Tracing ALXO's Return on Capital Employed over 5 years: stood at 44.91% in 2022, then slumped by 94 bps to 87.17% in 2023, then fell by 10 bps to 96.1% in 2024, then slumped by 134 bps to 224.51% in 2025, then jumped by 59 bps to 92.55% in 2026.
- Business Quant data shows ALXO's Return on Capital Employed at 92.55% in Q1 2026, 224.51% in Q4 2025, and 182.08% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Alx Oncology Holdings | 211.24 Mn | 211.24 Mn | - | -92.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -92.55% |
| Dec 31, 2025 | -224.51% |
| Sep 30, 2025 | -182.08% |
| Jun 30, 2025 | -136.28% |
| Mar 31, 2025 | -118.11% |
| Dec 31, 2024 | -96.10% |
| Sep 30, 2024 | -95.26% |
| Jun 30, 2024 | -103.08% |
| Mar 31, 2024 | -90.00% |
| Dec 31, 2023 | -87.17% |
| Sep 30, 2023 | -78.07% |
| Jun 30, 2023 | -56.40% |
| Mar 31, 2023 | -49.88% |
| Dec 31, 2022 | -44.91% |
| Sep 30, 2022 | -40.34% |
| Jun 30, 2022 | -33.72% |
| Mar 31, 2022 | -26.38% |
| Dec 31, 2021 | -22.30% |
| Sep 30, 2021 | -18.32% |
| Jun 30, 2021 | -14.07% |